First evaluation of QuantiFERON-TB Gold Plus performance in contact screening

Identifying latently infected individuals is crucial for the elimination of tuberculosis (TB). We evaluated for the first time the performance of a new type of interferon-γ release assay, QuantiFERON-TB Plus (QFT-Plus), which includes an additional antigen tube (TB2), stimulating both CD4 + and CD8...

Full description

Saved in:
Bibliographic Details
Published inThe European respiratory journal Vol. 48; no. 5; pp. 1411 - 1419
Main Authors Barcellini, Lucia, Borroni, Emanuele, Brown, James, Brunetti, Enrico, Campisi, Daniela, Castellotti, Paola F., Codecasa, Luigi R., Cugnata, Federica, Di Serio, Clelia, Ferrarese, Maurizio, Goletti, Delia, Lipman, Marc, Rancoita, Paola M.V., Russo, Giulia, Tadolini, Marina, Vanino, Elisa, Cirillo, Daniela M.
Format Journal Article
LanguageEnglish
Published England 01.11.2016
Subjects
Online AccessGet full text
ISSN0903-1936
1399-3003
DOI10.1183/13993003.00510-2016

Cover

Loading…
Abstract Identifying latently infected individuals is crucial for the elimination of tuberculosis (TB). We evaluated for the first time the performance of a new type of interferon-γ release assay, QuantiFERON-TB Plus (QFT-Plus), which includes an additional antigen tube (TB2), stimulating both CD4 + and CD8 + T-cells in contacts of TB patients. Contacts were screened for latent TB infection by tuberculin skin test, QFT-Plus and QuantiFERON-TB Gold in Tube (QFT-GIT). In 119 TB contacts, the overall agreement between QFT-Plus and QFT-GIT was high, with a Cohen's κ of 0.8. Discordant results were found in 12 subjects with negative QFT-GIT and positive QFT-Plus results. In analyses of markers of TB exposure and test results, the average time spent with the index case was the strongest risk factor for positivity in each of these tests. The difference in interferon-γ production between the two antigen tubes (TB2−TB1) was used as an estimate of CD8 + stimulation provided by the TB2. TB2−TB1 values >0.6 IU·mL −1 were significantly associated with proximity to the index case and European origin. QFT-Plus has a stronger association with surrogate measures of TB exposure than QFT-GIT in adults screened for latent TB infection. Interferon-γ response in the new antigen tube used an indirect estimate of specific CD8 + response correlates with increased Mycobacterium tuberculosis exposure, suggesting a possible role in identifying individuals with recent infection.
AbstractList Identifying latently infected individuals is crucial for the elimination of tuberculosis (TB). We evaluated for the first time the performance of a new type of interferon-γ release assay, QuantiFERON-TB Plus (QFT-Plus), which includes an additional antigen tube (TB2), stimulating both CD4+ and CD8+ T-cells in contacts of TB patients.Contacts were screened for latent TB infection by tuberculin skin test, QFT-Plus and QuantiFERON-TB Gold in Tube (QFT-GIT).In 119 TB contacts, the overall agreement between QFT-Plus and QFT-GIT was high, with a Cohen's κ of 0.8. Discordant results were found in 12 subjects with negative QFT-GIT and positive QFT-Plus results. In analyses of markers of TB exposure and test results, the average time spent with the index case was the strongest risk factor for positivity in each of these tests. The difference in interferon-γ production between the two antigen tubes (TB2-TB1) was used as an estimate of CD8+ stimulation provided by the TB2. TB2-TB1 values >0.6 IU·mL-1 were significantly associated with proximity to the index case and European origin.QFT-Plus has a stronger association with surrogate measures of TB exposure than QFT-GIT in adults screened for latent TB infection. Interferon-γ response in the new antigen tube used an indirect estimate of specific CD8+ response correlates with increased Mycobacterium tuberculosis exposure, suggesting a possible role in identifying individuals with recent infection.
Identifying latently infected individuals is crucial for the elimination of tuberculosis (TB). We evaluated for the first time the performance of a new type of interferon-γ release assay, QuantiFERON-TB Plus (QFT-Plus), which includes an additional antigen tube (TB2), stimulating both CD4 + and CD8 + T-cells in contacts of TB patients. Contacts were screened for latent TB infection by tuberculin skin test, QFT-Plus and QuantiFERON-TB Gold in Tube (QFT-GIT). In 119 TB contacts, the overall agreement between QFT-Plus and QFT-GIT was high, with a Cohen's κ of 0.8. Discordant results were found in 12 subjects with negative QFT-GIT and positive QFT-Plus results. In analyses of markers of TB exposure and test results, the average time spent with the index case was the strongest risk factor for positivity in each of these tests. The difference in interferon-γ production between the two antigen tubes (TB2−TB1) was used as an estimate of CD8 + stimulation provided by the TB2. TB2−TB1 values >0.6 IU·mL −1 were significantly associated with proximity to the index case and European origin. QFT-Plus has a stronger association with surrogate measures of TB exposure than QFT-GIT in adults screened for latent TB infection. Interferon-γ response in the new antigen tube used an indirect estimate of specific CD8 + response correlates with increased Mycobacterium tuberculosis exposure, suggesting a possible role in identifying individuals with recent infection.
Identifying latently infected individuals is crucial for the elimination of tuberculosis (TB). We evaluated for the first time the performance of a new type of interferon-γ release assay, QuantiFERON-TB Plus (QFT-Plus), which includes an additional antigen tube (TB2), stimulating both CD4 and CD8 T-cells in contacts of TB patients.Contacts were screened for latent TB infection by tuberculin skin test, QFT-Plus and QuantiFERON-TB Gold in Tube (QFT-GIT).In 119 TB contacts, the overall agreement between QFT-Plus and QFT-GIT was high, with a Cohen's κ of 0.8. Discordant results were found in 12 subjects with negative QFT-GIT and positive QFT-Plus results. In analyses of markers of TB exposure and test results, the average time spent with the index case was the strongest risk factor for positivity in each of these tests. The difference in interferon-γ production between the two antigen tubes (TB2-TB1) was used as an estimate of CD8 stimulation provided by the TB2. TB2-TB1 values >0.6 IU·mL were significantly associated with proximity to the index case and European origin.QFT-Plus has a stronger association with surrogate measures of TB exposure than QFT-GIT in adults screened for latent TB infection. Interferon-γ response in the new antigen tube used an indirect estimate of specific CD8 response correlates with increased Mycobacterium tuberculosis exposure, suggesting a possible role in identifying individuals with recent infection.
Author Brown, James
Cugnata, Federica
Ferrarese, Maurizio
Russo, Giulia
Borroni, Emanuele
Brunetti, Enrico
Castellotti, Paola F.
Lipman, Marc
Cirillo, Daniela M.
Codecasa, Luigi R.
Campisi, Daniela
Barcellini, Lucia
Goletti, Delia
Di Serio, Clelia
Vanino, Elisa
Tadolini, Marina
Rancoita, Paola M.V.
Author_xml – sequence: 1
  givenname: Lucia
  surname: Barcellini
  fullname: Barcellini, Lucia
– sequence: 2
  givenname: Emanuele
  surname: Borroni
  fullname: Borroni, Emanuele
– sequence: 3
  givenname: James
  surname: Brown
  fullname: Brown, James
– sequence: 4
  givenname: Enrico
  surname: Brunetti
  fullname: Brunetti, Enrico
– sequence: 5
  givenname: Daniela
  surname: Campisi
  fullname: Campisi, Daniela
– sequence: 6
  givenname: Paola F.
  surname: Castellotti
  fullname: Castellotti, Paola F.
– sequence: 7
  givenname: Luigi R.
  surname: Codecasa
  fullname: Codecasa, Luigi R.
– sequence: 8
  givenname: Federica
  surname: Cugnata
  fullname: Cugnata, Federica
– sequence: 9
  givenname: Clelia
  surname: Di Serio
  fullname: Di Serio, Clelia
– sequence: 10
  givenname: Maurizio
  surname: Ferrarese
  fullname: Ferrarese, Maurizio
– sequence: 11
  givenname: Delia
  surname: Goletti
  fullname: Goletti, Delia
– sequence: 12
  givenname: Marc
  surname: Lipman
  fullname: Lipman, Marc
– sequence: 13
  givenname: Paola M.V.
  surname: Rancoita
  fullname: Rancoita, Paola M.V.
– sequence: 14
  givenname: Giulia
  surname: Russo
  fullname: Russo, Giulia
– sequence: 15
  givenname: Marina
  surname: Tadolini
  fullname: Tadolini, Marina
– sequence: 16
  givenname: Elisa
  surname: Vanino
  fullname: Vanino, Elisa
– sequence: 17
  givenname: Daniela M.
  surname: Cirillo
  fullname: Cirillo, Daniela M.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27390280$$D View this record in MEDLINE/PubMed
BookMark eNp9kEtLxDAUhYMoOj5-gSBZuqnmNn1lqTIzCuqojOuQprcS6SRjkgr-e9vR2bhwdeHwncPlOyS71lkk5BTYBUDFL4ELwRnjF4zlwJKUQbFDJmOajPEumTDBeAKCFwfkMIR3NhAZh31ykJZcsLRiE_IwMz5Eip-q61U0zlLX0ude2Whm05fFY7K8pnPXNfSp6wNdo2-dXymrkRpLtbNR6UiD9ojW2LdjsteqLuDJ7z0ir7Pp8uY2uV_M726u7hOdQRGTcnisLlXKy0ZA1gJrspJpgVCUArFtKqZrBF5kdd3WKs9UlQuOIq0Ri6ZqNT8i5z-7a-8-egxRrkzQ2HXKouuDhCotShA5pAN69ov29QobufZmpfyX3CoYAPEDaO9C8NhKbeJGRfTKdBKYHHXLrW650S1H3UOX_-lu5_9rfQM9doBr
CitedBy_id crossref_primary_10_3389_fimmu_2024_1383098
crossref_primary_10_1183_20734735_0079_2021
crossref_primary_10_1513_AnnalsATS_201905_407RL
crossref_primary_10_1016_S1877_1203_19_30134_X
crossref_primary_10_1097_INF_0000000000002711
crossref_primary_10_14745_ccdr_v43i34a01
crossref_primary_10_1371_journal_pgph_0002077
crossref_primary_10_1371_journal_pone_0213304
crossref_primary_10_1128_spectrum_02445_21
crossref_primary_10_1007_s00296_023_05320_7
crossref_primary_10_1183_13993003_01267_2017
crossref_primary_10_1136_thorax_2022_218929
crossref_primary_10_1016_j_jinf_2017_07_004
crossref_primary_10_1007_s00430_018_00576_4
crossref_primary_10_1080_23744235_2017_1279747
crossref_primary_10_47429_lmo_2023_13_2_85
crossref_primary_10_1183_13993003_02563_2021
crossref_primary_10_1016_j_clinmicnews_2018_08_005
crossref_primary_10_7759_cureus_35706
crossref_primary_10_1016_j_tube_2017_11_014
crossref_primary_10_1155_2017_8909834
crossref_primary_10_3904_kjim_2019_002
crossref_primary_10_12688_gatesopenres_13191_2
crossref_primary_10_12688_gatesopenres_13191_3
crossref_primary_10_1183_13993003_01578_2017
crossref_primary_10_12688_gatesopenres_13191_1
crossref_primary_10_1016_j_tube_2017_06_002
crossref_primary_10_1128_Spectrum_00972_21
crossref_primary_10_1080_21505594_2021_1990660
crossref_primary_10_1016_j_jiac_2017_09_012
crossref_primary_10_1016_j_tube_2017_07_011
crossref_primary_10_1111_resp_13106
crossref_primary_10_1016_j_arbres_2020_04_011
crossref_primary_10_1016_j_jinf_2019_01_008
crossref_primary_10_1371_journal_pone_0193589
crossref_primary_10_1016_j_jinf_2019_01_007
crossref_primary_10_1016_j_lpm_2017_01_015
crossref_primary_10_3389_fimmu_2020_02006
crossref_primary_10_1016_j_ijid_2019_11_023
crossref_primary_10_1016_j_rppnen_2017_10_007
crossref_primary_10_1111_1744_9987_13939
crossref_primary_10_1016_j_rmed_2021_106508
crossref_primary_10_1371_journal_pgph_0003182
crossref_primary_10_1016_j_jctube_2024_100504
crossref_primary_10_1093_rheumatology_kez390
crossref_primary_10_3343_alm_2020_40_1_33
crossref_primary_10_1183_13993003_00896_2019
crossref_primary_10_1038_s41598_018_33825_w
crossref_primary_10_1097_MOP_0000000000000581
crossref_primary_10_1128_JCM_01360_17
crossref_primary_10_1016_j_rmr_2018_08_010
crossref_primary_10_1016_j_advms_2019_09_001
crossref_primary_10_1183_13993003_01089_2018
crossref_primary_10_1016_j_jiac_2021_08_016
crossref_primary_10_1016_j_jinf_2019_08_018
crossref_primary_10_1016_j_jinf_2020_02_009
crossref_primary_10_1136_thoraxjnl_2017_211147
crossref_primary_10_1183_13993003_04078_2020
crossref_primary_10_1183_23120541_00511_2021
crossref_primary_10_1080_23744235_2024_2313668
crossref_primary_10_1183_13993003_01630_2017
crossref_primary_10_58395_pipd_v47i1_15
crossref_primary_10_1093_clinchem_hvad220
crossref_primary_10_1128_JCM_00272_20
crossref_primary_10_1016_j_jmii_2023_07_014
crossref_primary_10_1016_j_jinf_2020_02_007
crossref_primary_10_1016_j_jiac_2020_06_019
crossref_primary_10_4236_jtr_2024_124013
crossref_primary_10_1016_j_jiac_2021_08_003
crossref_primary_10_1080_07853890_2020_1800073
crossref_primary_10_1097_INF_0000000000003173
crossref_primary_10_1016_j_jinf_2019_04_010
crossref_primary_10_1016_j_jiac_2020_01_011
crossref_primary_10_1183_13993003_01012_2016
crossref_primary_10_1016_j_arbres_2020_04_026
crossref_primary_10_1128_JCM_00985_19
crossref_primary_10_1016_j_pulmoe_2021_07_003
crossref_primary_10_1016_j_ebiom_2024_105196
crossref_primary_10_1128_JCM_00438_18
crossref_primary_10_1016_j_tube_2020_101966
crossref_primary_10_1016_j_ijid_2022_02_047
crossref_primary_10_1183_13993003_00391_2019
crossref_primary_10_1371_journal_pone_0234700
crossref_primary_10_1080_14737159_2017_1308825
crossref_primary_10_5144_0256_4947_2020_191
crossref_primary_10_3889_oamjms_2021_6859
crossref_primary_10_3389_fimmu_2021_619988
crossref_primary_10_4103_ijmy_ijmy_44_21
crossref_primary_10_1097_JOM_0000000000001904
crossref_primary_10_24293_ijcpml_v30i3_2212
crossref_primary_10_3390_ijerph14030236
crossref_primary_10_4103_ijmy_ijmy_112_22
crossref_primary_10_1128_JCM_01370_21
crossref_primary_10_1515_cclm_2023_0293
crossref_primary_10_1016_j_tube_2020_101959
crossref_primary_10_1128_JCM_01950_19
crossref_primary_10_1016_j_ccm_2019_07_002
crossref_primary_10_1186_s12879_023_08008_2
crossref_primary_10_1371_journal_pone_0187313
crossref_primary_10_1016_j_jctube_2019_100102
crossref_primary_10_1016_j_ccm_2019_07_007
crossref_primary_10_1016_j_jinf_2019_07_007
crossref_primary_10_1093_cid_ciad030
crossref_primary_10_1016_j_arbr_2021_06_002
crossref_primary_10_1007_s10067_021_05663_1
crossref_primary_10_1093_cid_ciaa1822
crossref_primary_10_1016_j_cca_2023_117559
crossref_primary_10_1038_s41598_020_78374_3
crossref_primary_10_1183_23120541_00258_2018
crossref_primary_10_2174_0118715265275319231124053615
crossref_primary_10_1128_JCM_00614_18
Cites_doi 10.1002/eji.201243262
10.4049/jimmunol.0801694
10.1183/09031936.00205512
10.1016/S0140-6736(00)02742-2
10.1056/NEJMra1405427
10.4049/jimmunol.1101122
10.1183/09031936.00089510
10.1016/S1473-3099(07)70086-5
10.1016/S0140-6736(15)01316-1
10.1164/rccm.201203-0430OC
10.1371/journal.pone.0018315
10.1164/rccm.200306-837OC
10.1016/S1473-3099(11)70210-9
10.1017/S095026881400394X
10.1086/382362
10.5588/ijtld.10.0631
10.1016/j.diagmicrobio.2012.11.023
10.1164/rccm.201107-1355OC
10.1016/j.jinf.2014.06.009
10.1164/ajrccm.149.5.8173779
10.1001/jama.282.7.677
10.1371/journal.pone.0043285
10.1183/13993003.00263-2015
10.1183/09031936.00114810
10.1183/13993003.02033-2015
10.1017/S0950268897007917
10.1371/journal.pone.0096564
10.1164/rccm.201412-2141OC
10.1016/j.jinf.2015.07.009
10.1183/09031936.00214014
10.1371/journal.pone.0032482
10.1016/j.ebiom.2015.01.009
ContentType Journal Article
Copyright Copyright ©ERS 2016.
Copyright_xml – notice: Copyright ©ERS 2016.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1183/13993003.00510-2016
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1399-3003
EndPage 1419
ExternalDocumentID 27390280
10_1183_13993003_00510_2016
Genre Journal Article
GroupedDBID ---
.55
.GJ
18M
1OC
2WC
31~
3O-
53G
5GY
5RE
5VS
8-1
AADJU
AAFWJ
AAYXX
AAZMJ
ABCQX
ABJNI
ABOCM
ABSQV
ACEMG
ACGFO
ACPRK
ACXQS
ADBBV
ADDZX
ADMOG
ADYFA
AENEX
AFFNX
AFHIN
AFZJQ
AIZTS
AJAOE
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CAG
CITATION
COF
CS3
DIK
E3Z
EBS
EJD
F5P
F9R
GX1
H13
INIJC
J5H
KQ8
L7B
LH4
LW6
OK1
P2P
PQQKQ
R0Z
RHI
TER
TR2
W8F
WOQ
X7M
ZE2
ZGI
ZXP
~02
CGR
CUY
CVF
ECM
EIF
NPM
RHF
7X8
ID FETCH-LOGICAL-c416t-7090b7a237d914f10d470c9e1679eefd80cbe1364bbfba54a8593e92bee6d8fc3
ISSN 0903-1936
IngestDate Thu Jul 10 18:35:58 EDT 2025
Wed Feb 19 02:42:34 EST 2025
Sun Jul 06 05:02:55 EDT 2025
Thu Apr 24 23:04:41 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License Copyright ©ERS 2016.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c416t-7090b7a237d914f10d470c9e1679eefd80cbe1364bbfba54a8593e92bee6d8fc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://erj.ersjournals.com/content/erj/48/5/1411.full.pdf
PMID 27390280
PQID 1826719512
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_1826719512
pubmed_primary_27390280
crossref_citationtrail_10_1183_13993003_00510_2016
crossref_primary_10_1183_13993003_00510_2016
PublicationCentury 2000
PublicationDate 2016-11-01
PublicationDateYYYYMMDD 2016-11-01
PublicationDate_xml – month: 11
  year: 2016
  text: 2016-11-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle The European respiratory journal
PublicationTitleAlternate Eur Respir J
PublicationYear 2016
References 2024102100071623000_48.5.1411.29
2024102100071623000_48.5.1411.28
2024102100071623000_48.5.1411.25
2024102100071623000_48.5.1411.24
2024102100071623000_48.5.1411.27
2024102100071623000_48.5.1411.26
2024102100071623000_48.5.1411.21
Farhat (2024102100071623000_48.5.1411.7) 2006; 10
2024102100071623000_48.5.1411.20
2024102100071623000_48.5.1411.23
Rangaka (2024102100071623000_48.5.1411.12) 2015; 12
2024102100071623000_48.5.1411.22
2024102100071623000_48.5.1411.30
2024102100071623000_48.5.1411.1
2024102100071623000_48.5.1411.18
2024102100071623000_48.5.1411.17
2024102100071623000_48.5.1411.19
2024102100071623000_48.5.1411.14
2024102100071623000_48.5.1411.36
2024102100071623000_48.5.1411.13
2024102100071623000_48.5.1411.35
2024102100071623000_48.5.1411.16
2024102100071623000_48.5.1411.15
2024102100071623000_48.5.1411.10
2024102100071623000_48.5.1411.32
2024102100071623000_48.5.1411.31
2024102100071623000_48.5.1411.34
2024102100071623000_48.5.1411.11
2024102100071623000_48.5.1411.33
2024102100071623000_48.5.1411.8
2024102100071623000_48.5.1411.9
2024102100071623000_48.5.1411.6
2024102100071623000_48.5.1411.4
2024102100071623000_48.5.1411.5
2024102100071623000_48.5.1411.2
2024102100071623000_48.5.1411.3
References_xml – ident: 2024102100071623000_48.5.1411.23
  doi: 10.1002/eji.201243262
– ident: 2024102100071623000_48.5.1411.25
  doi: 10.4049/jimmunol.0801694
– ident: 2024102100071623000_48.5.1411.3
  doi: 10.1183/09031936.00205512
– ident: 2024102100071623000_48.5.1411.8
  doi: 10.1016/S0140-6736(00)02742-2
– ident: 2024102100071623000_48.5.1411.1
  doi: 10.1056/NEJMra1405427
– ident: 2024102100071623000_48.5.1411.22
  doi: 10.4049/jimmunol.1101122
– ident: 2024102100071623000_48.5.1411.32
  doi: 10.1183/09031936.00089510
– ident: 2024102100071623000_48.5.1411.33
  doi: 10.1016/S1473-3099(07)70086-5
– ident: 2024102100071623000_48.5.1411.18
  doi: 10.1016/S0140-6736(15)01316-1
– ident: 2024102100071623000_48.5.1411.30
  doi: 10.1164/rccm.201203-0430OC
– ident: 2024102100071623000_48.5.1411.14
  doi: 10.1371/journal.pone.0018315
– ident: 2024102100071623000_48.5.1411.21
  doi: 10.1164/rccm.200306-837OC
– ident: 2024102100071623000_48.5.1411.29
– ident: 2024102100071623000_48.5.1411.27
– volume: 12
  start-page: 45
  year: 2015
  ident: 2024102100071623000_48.5.1411.12
  article-title: Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(11)70210-9
– ident: 2024102100071623000_48.5.1411.26
  doi: 10.1017/S095026881400394X
– ident: 2024102100071623000_48.5.1411.28
  doi: 10.1086/382362
– ident: 2024102100071623000_48.5.1411.11
  doi: 10.5588/ijtld.10.0631
– ident: 2024102100071623000_48.5.1411.24
  doi: 10.1016/j.diagmicrobio.2012.11.023
– ident: 2024102100071623000_48.5.1411.35
  doi: 10.1164/rccm.201107-1355OC
– ident: 2024102100071623000_48.5.1411.34
  doi: 10.1016/j.jinf.2014.06.009
– ident: 2024102100071623000_48.5.1411.6
  doi: 10.1164/ajrccm.149.5.8173779
– ident: 2024102100071623000_48.5.1411.4
  doi: 10.1001/jama.282.7.677
– ident: 2024102100071623000_48.5.1411.13
  doi: 10.1371/journal.pone.0043285
– ident: 2024102100071623000_48.5.1411.19
  doi: 10.1183/13993003.00263-2015
– ident: 2024102100071623000_48.5.1411.9
  doi: 10.1183/09031936.00114810
– ident: 2024102100071623000_48.5.1411.36
  doi: 10.1183/13993003.02033-2015
– ident: 2024102100071623000_48.5.1411.5
  doi: 10.1017/S0950268897007917
– ident: 2024102100071623000_48.5.1411.31
  doi: 10.1371/journal.pone.0096564
– ident: 2024102100071623000_48.5.1411.15
  doi: 10.1164/rccm.201412-2141OC
– ident: 2024102100071623000_48.5.1411.16
  doi: 10.1016/j.jinf.2015.07.009
– ident: 2024102100071623000_48.5.1411.2
  doi: 10.1183/09031936.00214014
– volume: 10
  start-page: 1192
  year: 2006
  ident: 2024102100071623000_48.5.1411.7
  article-title: False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?
  publication-title: Int J Tuberc Lung Dis
– ident: 2024102100071623000_48.5.1411.10
  doi: 10.1371/journal.pone.0032482
– ident: 2024102100071623000_48.5.1411.20
– ident: 2024102100071623000_48.5.1411.17
  doi: 10.1016/j.ebiom.2015.01.009
SSID ssj0016431
Score 2.548529
Snippet Identifying latently infected individuals is crucial for the elimination of tuberculosis (TB). We evaluated for the first time the performance of a new type of...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 1411
SubjectTerms Adult
Aged
CD4-Positive T-Lymphocytes - cytology
CD8-Positive T-Lymphocytes - cytology
Contact Tracing - methods
Cross-Sectional Studies
Female
Humans
Incidence
Interferon-gamma
Interferon-gamma Release Tests - methods
Italy
Latent Tuberculosis - diagnosis
Latent Tuberculosis - transmission
Male
Middle Aged
Models, Statistical
Mycobacterium tuberculosis
Tuberculin Test - methods
Tuberculosis, Pulmonary - diagnosis
Title First evaluation of QuantiFERON-TB Gold Plus performance in contact screening
URI https://www.ncbi.nlm.nih.gov/pubmed/27390280
https://www.proquest.com/docview/1826719512
Volume 48
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWIiEuqDy7tCAjcSspTuK8jgV2KaBFgLZSb1EcO1LQ4lTb5NJf3xnHSVzRIuASrRzvOJr5NJ7xPEzIax5LKaO48MoiyTwOm4gnWCq8GOZjnEwVGRYnr77GJ6f881l0NptVTtZS14qj8vLGupL_kSqMgVyxSvYfJDsShQH4DfKFJ0gYnn8l42UNtpvTsBstv-8d8KpeLn6Ajly_O_zYbOTht013gQ2KxxIBk3yuW6yPBLUBruywgf2cwDOe02-daLz7Web805z817qvse7KevLvmy223TW6Fhbt1MaJ31vX36ToTqOdVm2fXbDQoJ4b90TCj21pntlQei0KVo8XMha6apanDpwiR2f6vFe3vyvzFJtKIDGkdWT0h4cLurNBIue_jHzBEDOtaKadbcw3HF7dIXcDcCfwposPn76M0SawynzbkQrWfHvDitgz2tK4bsDc4pUY62S9Sx5Yt4Ie9xh5SGZKPyL3VjZx4jFZGajQCSq0qeh1qFCECkWoUAcqtNbUQoWOUHlCTpeL9fsTz96k4ZVgcLdewjImkiIIE5n5vPKZ5AkrM4UxOKUqmbJSKD-MuRCVKCJeYBc8lQVCqVimVRk-JTu60WqP0FgCqYoBjYJzFkiRJoUIS8VkpdKoSuYkGNiTl7bNPN52ssmNu5mG-cDe3LA3R_bOyZvxT-d9l5U_T3818D0HbYhAL7RquoscveXEB68hmJNnvUBGgoMAn9_6Zp_cn_B8QHbabadegM3ZipcGMFfNuH0I
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=First+evaluation+of+QuantiFERON-TB+Gold+Plus+performance+in+contact+screening&rft.jtitle=The+European+respiratory+journal&rft.au=Barcellini%2C+Lucia&rft.au=Borroni%2C+Emanuele&rft.au=Brown%2C+James&rft.au=Brunetti%2C+Enrico&rft.date=2016-11-01&rft.eissn=1399-3003&rft.volume=48&rft.issue=5&rft.spage=1411&rft_id=info:doi/10.1183%2F13993003.00510-2016&rft_id=info%3Apmid%2F27390280&rft.externalDocID=27390280
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0903-1936&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0903-1936&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0903-1936&client=summon